PMID- 38078671
OWN - NLM
STAT- Publisher
LR  - 20231211
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
DP  - 2023 Dec 11
TI  - Nasal instillation of povidone-iodine ameliorates ongoing mucosal inflammation in 
      a pre-sensitized murine model of Der p1-induced allergic rhinitis.
LID - 10.1002/alr.23308 [doi]
AB  - BACKGROUND: Interleukin (IL)-33, when cleaved into smaller fragments by 
      proteases, becomes hyperactive, contributing to allergic inflammation. 
      Povidone-iodine (PVP-I) is an iodine-based compound that exhibits antimicrobial 
      properties and inhibits proteases. This study aimed to investigate whether PVP-I 
      treatment inhibits IL-33 cleavage, improves allergic rhinitis (AR) symptoms, and 
      suppresses allergic inflammation in a mouse model. METHODS: In vitro experiments 
      using full-length recombinant human IL-33 and allergens, including house dust 
      mites or Dermatophagoides pteronyssinus 1, were conducted using western blotting. 
      Fifty BALB/c mice were divided into five groups: control (CON), AR with 
      phosphate-buffered saline treatment (AR), PVP-I treatment (AR + PVP), 
      trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane (E64) treatment (AR + E64), 
      and dexamethasone treatment (AR + Dexa). Nasal symptom scores, including rubbing 
      and sneezing, were measured. The cytokine levels in the nasal lavage fluid (NLF) 
      and the concentration of immunoglobulins in the blood serum were assessed. Nasal 
      mucosa from each group was used for reverse transcriptase-polymerase chain 
      reaction (RT-PCR) and histological analyses were conducted. RESULTS: PVP-I 
      treatment reduced nasal symptoms, suppressed allergic inflammation, and decreased 
      the levels of IL-33, IL-5, and IL-13 in the NLF and total immunoglobulin E (IgE) 
      and specific IgE in the serum. Histopathological analysis revealed a reduction in 
      the number of eosinophils and goblet cells in the nasal mucosa of the AR + PVP 
      group when compared to the AR group. RT-PCR and immunofluorescence staining 
      confirmed the downregulation of genes and proteins associated with allergic 
      inflammation. CONCLUSIONS: These findings suggest that nasal irrigation with 
      PVP-I may be a promising therapeutic option for managing AR by inhibiting IL-33 
      activation and suppressing allergic inflammation.
CI  - (c) 2023 ARS-AAOA, LLC.
FAU - Kang, Jae-Yoon
AU  - Kang JY
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for 
      Medical Science, Chungnam National University, College of Medicine, Daejeon, 
      South Korea.
FAU - Choi, Mi-Ra
AU  - Choi MR
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for 
      Medical Science, Chungnam National University, College of Medicine, Daejeon, 
      South Korea.
FAU - Kim, Yong Min
AU  - Kim YM
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Research Institute for 
      Medical Science, Chungnam National University, College of Medicine, Daejeon, 
      South Korea.
LA  - eng
GR  - 2019R1I1A3A01061632/National Research Foundation of Korea/
GR  - Chungnam National University/
PT  - Journal Article
DEP - 20231211
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
SB  - IM
OTO - NOTNLM
OT  - allergens
OT  - allergic rhinitis
OT  - irrigation
OT  - nose models
EDAT- 2023/12/11 12:41
MHDA- 2023/12/11 12:41
CRDT- 2023/12/11 08:35
PHST- 2023/11/06 00:00 [revised]
PHST- 2023/08/05 00:00 [received]
PHST- 2023/11/28 00:00 [accepted]
PHST- 2023/12/11 12:41 [medline]
PHST- 2023/12/11 12:41 [pubmed]
PHST- 2023/12/11 08:35 [entrez]
AID - 10.1002/alr.23308 [doi]
PST - aheadofprint
SO  - Int Forum Allergy Rhinol. 2023 Dec 11. doi: 10.1002/alr.23308.